Hylase Wound Gel is indicated for the management and treatment of leg ulcers, pressure ulcers, diabetic ulcers and exuding wounds prone to bleeding.
ECR Pharmaceuticals, Hi-Tech’s branded subsidiary, will promote Hylase to physicians, hospitals and nursing care facilities.
The hyaluronic acid and emollient based gel is a proprietary patented device approved by the FDA pursuant to Section 510 (k).
Hi-Tech president and CEO David Seltzer said with the patented FDA approved device they will expand the portfolio of products and reach additional markets and a growing patient population.